ABOUT US

Core Values of Dravya

  • Scientific Excellence
    We are committed to high-quality science that delivers reliable, reproducible, and decision-enabling data.
  • Translational Focus
    We prioritise human-relevant models and clinically meaningful endpoints to improve predictability and accelerate ophthalmic drug development.
  • Integrity & Trust
    We operate with transparency, accountability, and ethical responsibility in all our research, partnerships, and data reporting.
  • Collaboration
    We work as an extension of our collaborators’ teams, combining scientific insight with regular communication to achieve shared goals.
  • Innovation with Purpose
    We continuously evolve our platforms to solve real challenges in ophthalmology and drive clinical impact.
  • Patient Impact
    Everything we do is driven by enabling therapies that protect, restore, and improve vision.
Advancing Ophthalmology Drug Discovery Through Human-Relevant Models

Dravya Discovery supports biotech and pharmaceutical companies with advanced preclinical in vitro models and translational research services focused on ophthalmic diseases, helping accelerate the development of innovative therapies for vision-threatening conditions.

30+ Years of Scientific Expertise

Our team combines deep expertise in ocular biology, disease modelling, and translational research to deliver reliable preclinical data that supports early drug discovery and development programmes.

Accelerating Ocular Therapeutics

From target validation to functional bioassays, our services help partners generate high-quality data to support decision-making across early-stage ophthalmology drug development.

Book An Appointment

Visual acuity test sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et

Book an appointment
FAQs

Frequently Asked Questions


Discuss how regular eye exams can detect vision problems early on and more

Dravya Discovery provides preclinical in vitro research services focused on ophthalmology drug discovery and early translational research. Our services include human cell-based disease models, assay development, target validation, mechanistic studies, and efficacy testing across a range of ocular indications.

We support research across multiple ophthalmic indications, including:

  • Age-related macular degeneration (AMD)
  • Diabetic retinopathy
  • Retinal degeneration
  • Glaucoma
  • Dry eye disease
  • Corneal inflammation and fibrosis
  • Uveitis
  • Ocular inflammation

We can also develop custom disease models tailored to specific research questions.

We use human-relevant cell-based models to replicate key disease mechanisms in the eye. These may include:

  • Primary ocular cells
  • Immortalized cell lines
  • Co-culture models
  • Inflammation models
  • Fibrosis models
  • Barrier function assays
  • Retinal and corneal cell systems

These models help evaluate drug efficacy, mechanism of action, and safety signals early in the discovery process.

Yes. In addition to established assays, we frequently develop bespoke experimental models and assays designed around specific drug targets, pathways, or therapeutic mechanisms.

Our scientists work closely with clients to ensure the assay captures relevant disease biology and delivers actionable data.